Phase 2 N=14 Estradiol Levels in Patients Treated With Estring
Estrogen Levels Among Breast Cancer Patients
Primary: Changes in Serum Estradiol — 3.9 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
Atrophic Vaginitis · Breast Cancer
Primary: Change in Serum Estradiol From Baseline to Week 12 — 5.21; 4.46; 5.23; 6.72 pg/ml
Phase 2 N=66 Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Phase 2 N=47 Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Breast Cancer
Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV
N/A N=123 Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02
Breast Cancer
Primary: Estrogen Levels (Estradiol [E2], Estrone [E1], and Estrone Sulphate [E1S]) at Different Time Points During the First 4 Years of Treatment With Triptorelin (Trip) in…
N/A N=13 Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
N/A N=104 Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07
Breast Cancer
Primary: Levels of Estrone (E1), Estradiol (E2), and Estrone Sulphate (E1S) Among Patients in the Longitudinal Analysis Population — 12.4; 14.3; 4.8; 5.1 pg/mL
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Phase 4 N=40 RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
Breast Cancer · Infertility
Primary: Mature Oocyte Yield — 5.1; 7.9 oocytes — p=0.31
Early Phase 1 N=95 Melatonin Versus Placebo in Breast Cancer
Breast Cancer
Primary: Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo — 4.59; 3.39 pg/ml — p=<0.05
Phase 2 N=180 Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Stage 0 Breast Cancer AJCC v6 and v7 · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change
N/A N=82 Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
Oral Contraceptive
Primary: Breast Cell Proliferation Levels Between the Three Oral Contraceptive Groups — 8.5; 11.9; 7.5 Percent of cells staining for Ki67
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
N/A N=59 Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Breast Cancer
Primary: Mean Percent Positive Proximity Ligation Assays of All Tumor Protein p53-wild Type Breast Tumors in Participants by Treatment Arm — 27.0; 4.4 percentage of positive PLA
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 1 N=27 A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
Postmenopause
Primary: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 — 0.028; -0.011…
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=36 Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 4.3 months
N/A N=266 Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
Breast Cancer
Primary: Change in Absolute Breast Density — 65.53; 64.39; 65.08; 56.35 cm squared
Phase 3 N=263 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Primary: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) — -4.63; 0.37 Percent Change
Phase 2 N=120 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) Determined by Clinical Palpation — 58.9; 53.8 percentage of participants
Phase 2 N=48 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Phase 3 N=622 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Breast Cancer
Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
N/A N=30 Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Breast Cancer
Primary: Change in Mammographic Breast Density Over Course of Study — -0.5 Change in percent dense breast area
Phase 2 N=197 Soy Isoflavones and Breast Cancer Risk Reduction
Breast Cancer
Primary: Fibroglandular Tissue in Total Breast (FGBT%) — 24.94; 25.34; 24.03; 25.82 percentage of total breast tissue — p=0.071
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…